Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137853 | 1.00 | F10 (0.65) | F10PTGS2FPR2MTORANPEP | |
| SCHEMBL3130895 | 0.90 | F10 (0.65) | F10PTGS2MTOR | |
| SCHEMBL3130918 | 0.90 | F10 (0.65) | F10PTGS2MTOR | |
| SCHEMBL3126166 | 0.89 | F10 (0.79) | F10PTGS2MTOR | |
| SCHEMBL3132856 | 0.89 | F10 (0.65) | F10PTGS2MTOR | |
| SCHEMBL3126191 | 0.89 | F10 (0.79) | F10PTGS2MTOR | |
| SCHEMBL3132838 | 0.89 | F10 (0.65) | F10PTGS2MTOR | |
| SCHEMBL14078400 | 0.85 | F10 (0.60) | F10PTGS2MTOR | |
| SCHEMBL4494790 | 0.85 | F10 (0.71) | F10PTGS2 | |
| SCHEMBL4494801 | 0.85 | F10 (0.71) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1597244-B1 | ETHYNYL DERIVATIVES SERVING AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2010-07-07 | — | — | EP | claimed |
| US-7427618-B2 | Ethynyl derivatives as factor Xa inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-09-23 | — | — | US | claimed |
| US-20060084648-A1 | Ethynyl derivatives as factor xa inhibitors | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | US | claimed |
| US-7427618-B2 | Ethynyl derivatives as factor Xa inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20060084648-A1 | Ethynyl derivatives as factor xa inhibitors | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084648-A1 | Ethynyl derivatives as factor xa inhibitors | F12, F11, SERPINC1 | F10 4/4885PTGS2 2299/4885FPR2 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.